BIOMAT Database Logo BIOMAT Database Logo

Dopaminergic regulation of aldosterone secretion: its pathophysiologic significance in subsets of primary aldosteronism. 1995

M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
Department of Medicine, Tokyo Women's Medical College, Japan.

Although aldosterone (Aldo.) secretion is regulated by various humoral factors, evidence has accumulated to support an involvement of dopaminergic system in its regulation. The pathophysiological significance of the dopaminergic system in primary aldosteronism (PA) however remains unknown. In the present study, we examined the effects of metoclopramide (MCP) on Aldo. secretion in normal subjects (n = 11) and patients with essential hypertension (EH, n = 8), aldosterone-producing adenoma (APA, n = 10), and idiopathic hyperaldosteronism (IHA, n = 6). Plasma Aldo., prolactin (PRL), renin, cortisol, serum sodium, and serum potassium levels were determined before and 30 min after i.v. bolus injection of 10 mg MCP at 9 a.m. Plasma Aldo. showed a significant increase after MCP in normal subjects, EH, and APA, but not in IHA. The incremental response of plasma Aldo. was largest in APA and smallest in IHA. The percentage increase in plasma Aldo. from the basal level was significantly attenuated in IHA, while no significant difference was seen among other groups. Although plasma PRL showed a significant increase in response to MCP, no difference of the change was seen among the groups. There was no significant change in plasma cortisol, renin, serum sodium, and serum potassium levels in response to MCP. In addition, the response of Aldo. to MCP was normalized in APA after unilateral adrenalectomy, while that of PRL did not change. These results indicate that the adrenal dopaminergic activity is enhanced in APA and attenuated in IHA and suggest an involvement of the dopaminergic system in the pathogenesis of IHA.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008787 Metoclopramide A dopamine D2 antagonist that is used as an antiemetic. 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide,Cerucal,Maxolon,Metaclopramide,Metoclopramide Dihydrochloride,Metoclopramide Hydrochloride,Metoclopramide Monohydrochloride,Metoclopramide Monohydrochloride, Monohydrate,Primperan,Reglan,Rimetin,Dihydrochloride, Metoclopramide,Hydrochloride, Metoclopramide,Monohydrochloride, Metoclopramide
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's

Related Publications

M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
Regulation of aldosterone secretion in primary aldosteronism.
September 1975, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
[Endogenous dopaminergic regulation of aldosterone secretion. Studies of pathophysiologic value].
June 1987, Fortschritte der Medizin,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
The regulation of aldosterone secretion in primary aldosteronism.
November 1972, The American journal of medicine,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
Dopaminergic regulation of aldosterone secretion: assessment in different subtypes of primary aldosteronism and in essential hypertension.
January 1991, The Journal of international medical research,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
[Aldosterone secretion in primary aldosteronism].
January 1975, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
Aldosterone regulation in primary aldosteronism.
September 1994, European journal of endocrinology,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
Activation of aldosterone secretion in primary aldosteronism.
January 1969, The Journal of clinical investigation,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
[Primary aldosteronism with normal secretion of aldosterone].
September 1971, Nihon rinsho. Japanese journal of clinical medicine,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism.
February 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M Naruse, and K Naruse, and T Yoshimoto, and M Tanaka, and A Tanabe, and T Imaki, and T Shibasaki, and R Demura, and H Demura
Dopaminergic regulation of aldosterone secretion: how credible?
June 1984, Clinical science (London, England : 1979),
Copied contents to your clipboard!